Cancer in the Small Developing Island States of the Eastern Caribbean (CaSIDEC)

July 4, 2026 updated by: Dr Aviane Auguste, Vaughan A. Lewis Institute for Research and Innovation

Overseas Care and Cancer Survivorship in Small Island Developing States of the Eastern Caribbean

Caribbean studies examining overseas cancer care were lacking patient-level data. Investigators will collect data from patients by establishing a cohort of survivors across six small island developing states (SIDS) (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia and Saint Vincent). This proposal is novel for the Caribbean, and it is the first step in identifying the critical performance gaps and leverage points in the process of overseas referral for cancer care. Investigators will compare for the first time, the characteristics and experiences of Caribbean cancer survivors in SIDS who seek care overseas to those who received care on-island.

My overarching goal is to investigate the effects of overseas travel for care on patient-centered outcomes in Caribbean SIDS, and to build a research resource to study cancer survival, as I develop my career as an independent mixed-method investigator.

Our primary aims are to (P1): Map patterns of overseas travel for cancer care among cancer survivors of six member states of the OECS and (P2): Explore the lived experience of cancer survivors and caregivers and how overseas travel for care affects their social support systems.

Investigators anticipate that (H1) a substantial proportion of cancer survivors travel outside of their resident country for cancer. We expect certain destinations to be more frequented among cancer survivors by individual characteristics (cancer site, stage and country of residence). We also expect that (H2) overseas care may be associated with both challenges and adaptations in social support systems, as explored qualitatively through survivor and caregiver accounts.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

CaSIDEC is an acronym for "Cancer in SIDS of the Eastern Caribbean". Our overarching ambition is to explore how overseas travel for care may affect key domains of cancer survivorship. Survivorship will be our long-term focus and goes beyond survival as commonly measured in clinical trials (i.e. time to death from diagnosis) and will include measures on how individuals experience life with cancer. In this study, overseas care will be considered as any travel across international country borders (including the Caribbean) regardless of the payment mechanism (e.g. out of pocket or government subsidized).

As a first step, investigators wish to contribute towards building research capacity in SIDS. The CaSIDEC study aims to generate foundational evidence on transnational cancer care pathways and survivorship in SIDS of the Eastern Caribbean. Given the limited availability of standardized epidemiological data in this region, investigators wish to establish data resources, measurement approaches, and analytic frameworks necessary to support future hypothesis-driven and causal research on this topic.

In terms of impact, the data from the current study will guide decisions at the patient, provider and policy level. It will inform notably decisions on how overseas referral pathways should be organized across the OECS subregion.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
900

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia and Saint Vincent

Description

Inclusion Criteria:

  • Primary aim 1 (P1): We will include cancer survivors 18 years of age or older, able to communicate in English or local dialect (without cognitive impairment), with an invasive cancer diagnosis (any cancer site, histology, and year of diagnosis), and having accessed health services in their island of residence (i.e. Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia and Saint Vincent ) due to their cancer. Participation will include written authorization to access each patient's data from medical records in health care institutions and centers
  • Primary aim 2 (P2): For the qualitative segment of this proposal, field investigators across the 6 islands will purposefully identify cancer survivors and caregivers of survivors who (1) are receiving or already finished their initial active treatment at the time of the study, (2) received a treatment requiring the intervention of a medical professional (e.g. surgery, chemotherapy, radiotherapy), and (3) are willing to provide written consent for one-on-one interviews and/or focus group discussions.

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Informal caregivers
Informal caregivers of cancer survivors diagnosed in the Eastern Caribbean
Other: Overeseas travel for care
Cancer survivors who travel overseas travel for care (observation)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Destination country for cancer treatment
Time Frame: At inclusion (0 days)
We will map and characterize patterns of overseas care.We will compute the proportion or cancer survivors who travelledtraveled overseas for diagnosis and treatment among the entire sample. The proportion of overseas travel will be computed as well by cancer site, OECS country, period of diagnosis, and type of diagnostics and treatment accessed. Where possible we will characterize overseas travel by region (Caribbean, North America, South America, Europe, and other) and by destination country.
At inclusion (0 days)
Social support system
Time Frame: At inclusion (0 days)
Qualitative interviews for social support will be initiated by an introductory question "describe the support you received during the cancer journey", then guided by questions and prompts "who", "what was the relationship to you? such as a family, friend, neighbours" and "when". Participants will be encouraged to focus on aspects of the day-to-day logistics and travel arrangements, experience living overseas.
At inclusion (0 days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Vaughan A. Lewis Institute for Research and Innovation

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Aviane Auguste, PhD, Vaughan A. Lewis Institute for Research and Innovation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 16, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 15, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 15, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 19, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 4, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 10, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 4, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • A10-M79-24A

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymised data set containing basic sociodemographic and clincal characteristics of the persons included in the final sample.

IPD Sharing Time Frame

To be defined. We intend to publish manuscripts from this work. Data availablity is expected approximately 4 years after the end of data collection with no end date

IPD Sharing Access Criteria

To be determined

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings